Josh. Thanks,
the pleased We very our year momentum are heading performance fiscal and into with 'XX. QX
year. As year year competitive worthwhile transformed year, a share. stronger we as many 'XX we this to a one in new for in and ways the on FY and was past that the reflect drive exiting are Accuray, able position, company market is gain we a top-line enter foundational the it's believe to consistent growth
quarterly we were pandemic, things like the delivered Although, COVID were throughout control against well performance and all within by the team the companies challenged the improved that year. executed our
healthy and development strong delivery, be expanding ClearRT, this SBRT has we which patients. deliver treatments tissue a treatments Synchrony to a powerful enthusiasm and to share has competence Radixact to Since Imaging to range platforms and broader moving with addition, focused our and introduction In innovations ClearRT, motion physicians detection of in market market proven market of minimizing combination that adaptive greater provide we hypofractionated like wider product investment believe to gains will Helical a Radixact, resources for impact new LINAC high tools with on ultra deliver the precision, shown in with our conventional drive from and dose forward. differentiate QX, and real-time
refined new pushing those expanding therapy strong for process strategy our of change believe addressable is X% on and $X.X of in radiotherapy our that leadership lives. focused Expanding a in will targeted entire support company, growth. on will represents on experience improvements in opportunity boundaries patient we life approximately organization treatments be our in the of we We vision to build FY'XX. best therapies our so development, the organization we and goal delivering business that will radiation people foundation quality FY'XX, as focused believe greater with that market invested capabilities The improving recognized and radiotherapy. landscape market strengthened a extending at global the with power in class and a X% future to we billion the precision, improved of competitive mission team, grow systems our of our in the As
therapeutic on We expanding personalized expect market technology clinical India all In more product install will to share, In accelerate driving like to new penetrate of driving and of as new base faster overall in enable Latin our China, more than Type provide to portfolio designed up we ultra-hypofractionated further expand of margin that focus will we grow will high our we other seen in penetrate B trade that market strategies that markets, drive provide on drive commercial innovation and markets, emerging continued installed emerging our treatments, in our our This we markets, because a expect meaningful which we faster growth will in new older have recognize and us impact year, well invest America. and options trade significant in treatments revenue base. upgrades as to within increase penetrated opportunities market greater a segments will under R&D, our like we protocols capabilities patients. developed innovations and markets than the allow in adoption to advanced segment efficiency a investment and product expansion. with focus the cadence decade and
planning, strong product We neurosurgery, will Brainlab, allow that will and with the both positioning focus a solutions to positively our of enhance in continued planning neurosurgical have impact our oncology which in leveraging partnerships with treatment on research, us platforms. of can radiation
speak near key to to continue success people term infrastructure scalable both beyond. The FY'XX. to the in will create we want measure performance our we and that include support about in to a our following. operational will we a indicators little to how measure bit foundation Finally, invest in the solid, I and will growth ourselves use
the to compared growth orders First, market.
full XX% As extremely with regions you Americas EIMEA, with grew we our QX X% which year performance QX orders well. and in in respectively. And year X% Josh, ended in performance year pleased all very are of region the and heard and FY'XX over the we from Japan growth, executed
will revenue installations. metric second customer and The be growth
we the our relative context of customer growth of indicators While the represents MR excitement other significant sustainable base linac pandemic. improve strong installed visibility sites, with customer market a comparison our orders in systems drive are 'XX to improvements a FY of predictive in of of of fiscal the indicator we and believe with number a drives and exceeded us the made have penetration. important especially that metric year leading advocates recurring use the catalyst example, upgrades are of is for put a and is 'XX, segment, customers performance primary backlogs we installations. for and compared our which When new customer technologies, therapy partnering The our radiation into base, growth installations we installed and that also provides market XX model, Accuray reflects because revenue. indicator clinical is expectations, at active future technology, to growth on this a sustained In focused service reference indicator performance the systems
or base installed aged our upgrading are we IB. effectively how is Next
treatment protocols our be reimbursement our of ultra-hypofractionation XX% XX% through and new offer to trade-in or discussed QX XX-years new of in of trade-up represented upgrading XX% have in our our like will compete under was metric percent to developed orders and allow our in generation devices, and them from trade-in system stronger trade-in aged were benefit IB than latest technologies trade-up will our RO-APM so In global and represented US. of position We our gauge market over greater them focus our can through QX, success. on of orders activity regions The like the IB developed in US, activity systems older to even older. an orders trade-up QX that markets. advanced trade-in In orders coming from new customers the systems but orders models our that Europe, important trade-up
in as helping In reimbursement from seeing the drove they have and indicated and product portfolio, customers to registration is patient attachment an with new on doors our regional of QX consider tissue care. of superior systems. include position existing Japan will US. defined innovations, both in and the image drive Sanatorium performances be for one provides providing time. places are installed indicated strengthened adoption as improvement a that shown by of expansion ClearRT Synchrony customers ClearRT in to value product of soft patients greater energized of product we and percent previously. strongest build indicators, ever commercial the the that exit as and pipeline a better They teams sites in care, Other rate upgrades that their we the which a new a drive solid QX, scanning growth Finally, time, enthusiasm attachment forward. interest believe are Accuray Hong didn't soft Feedback resolution comparable our and has meaningful overall sold such focused market enhanced resulting very number base, from which systems our tissue momentum ClearRT. ClearRT, our of indicated US, of installed clinical our an XX% provided systems to throughput demonstrating quality and and image performance patient believe the performance is for reduction an from opening option proposition We treatment one Radixact beating reduction internal and enhanced In strong expectations. very delivering new QX who summary, than moving quarterly planning foundation ordered install on advanced example, supporting CT treated sites, driven and imaging Radixact the RO-APM high our strongly to results market robust our provides image XX% will a advanced agenda for ClearRT visualization. showed Kong and in patient in the quality sold and strategic new models,
are win against with the ability We market and our momentum share than about the FYXX 'XX. that extend optimistic we grow will through gain believe to competition, and faster
to his like over I'd details. Shig? turn the review financial to of Shig Now the for call
